Get started
Author

Isabelle Van Praagh

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study
2014 · Pierre Soubeyran, Carine Bellera, et al. · PLoS ONE · 622
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
2019 · Xavier Pivot, Gilles Romieu, et al. · The Lancet · 131
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
2014 · J.M. Nabholtz, C. Abrial, et al. · Annals of Oncology · 126
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy
2002 · S. Amat, F. Penault-Llorca, et al. · International Journal of Oncology · 123
Clinical and pathological response to primary chemotherapy in operable breast cancer
1997 · P. Chollet, S. Charrier, et al. · European Journal of Cancer · 114
Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial
2004 · Pierre Fargeot, Jacques Bonneterre, et al. · Journal of Clinical Oncology · 106
PDF
Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group
2004 · Jacques Bonneterre, Henri Roché, et al. · Journal of Clinical Oncology · 99
PDF
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
2021 · Judith Passildas‐Jahanmohan, Jean‐Christophe Eymard, et al. · Cancer Medicine · 66
PDF
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer
2015 · J.M. Nabholtz, N. Chalabi, et al. · International Journal of Cancer · 60
PDF
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer
2009 · Jean-Marc Nabholtz, Marie-Ange Mouret-Reynier, et al. · Expert Opinion on Pharmacotherapy · 33
Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors
2012 · E. Thivat, I. Van Praagh, et al. · Oncology · 24
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
2010 · S. Guiu, M. Liegard, et al. · Annals of Oncology · 22
Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer
2002 · Isabelle Van Praagh, Hervé Cure, et al. · The Oncologist · 18
PDF
Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments
2018 · Angeline Ginzac, Émilie Thivat, et al. · Clinical Breast Cancer · 17
Pre- and Postoperative Aminoacidemia in Breast Cancer: A Study vs. Matched Healthy Subjects
2004 · Régine Minet-Quinard, Isabelle Van Praagh, et al. · Cancer Investigation · 14
Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer
2005 · Catherine Abrial, Isabelle Van Praagh, et al. · The Oncologist · 12
Évaluation de l’observance des thérapeutiques orales en oncologie : résultats d’une étude pilote
2011 · R. Chevrier, Isabelle Van Praagh, et al. · Journal de Pharmacie Clinique · 10
[First-line chemotherapy in operable breast neoplasms: results of 3 protocols].
1997 · H Cure, S Charrier, et al. · PubMed · 9
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line
2015 · Mélanie Pouget, Catherine Abrial, et al. · Oncology · 6
Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression
2007 · T. Bachelot, L. Mauriac, et al. · Journal of Clinical Oncology · 6
Vinorelbine, Epirubicin, and Methotrexate (VEM) as Primary Treatment in Locally Advanced Breast Cancer
2001 · J. Abrahamova, M. Wagnerova, et al. · The Oncologist · 6
PDF
Efficacy of a chemotherapy regimen combining Vinorelbine, Epirubicine and Methotrexate (VEM) in locally advanced and metastatic breast cancer
1994 · I. Van Praagh, N. Martineau, et al. · Cancer Treatment An Update · 6
[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].
2006 · Marie-Ange Mouret-Reynier, Catherine Abrial, et al. · PubMed · 4
Everolimus Plus Hormonotherapy (Ht) Induces Survival Gain in Late Metastatic Breast Cancer (Mbc) After Progression: Could this Line Be Better Than a Late New Chemotherapy (Ct) Line?
2014 · M. Pouget, E. Planchat, et al. · Annals of Oncology · 3
Everolimus in metastatic breast cancer (MBC): Clinical experience as a late treatment line.
2015 · Mélanie Pouget, Catherine Abrial, et al. · Journal of Clinical Oncology · 1
Works count: 38
Citation count: 1,640
H-index: 14
I10-index: 17
Year
Topic
Type